Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Expands By 225.2%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 2,224,050 shares, a growth of 225.2% from the August 15th total of 683,892 shares. Based on an average trading volume of 40,219,957 shares, the short-interest ratio is presently 0.1 days. Approximately 17.5% of the company’s stock are sold short.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of VolitionRX during the 3rd quarter worth $28,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRX during the second quarter valued at about $52,000. Jane Street Group LLC purchased a new stake in VolitionRX during the fourth quarter worth about $28,000. Squarepoint Ops LLC purchased a new stake in VolitionRX during the fourth quarter worth about $34,000. Finally, Citadel Advisors LLC raised its position in VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares during the period. Institutional investors own 8.09% of the company’s stock.

VolitionRX Price Performance

Shares of NYSEAMERICAN VNRX traded down $0.00 during trading on Monday, hitting $0.31. The stock had a trading volume of 1,704,063 shares, compared to its average volume of 3,031,101. The firm has a fifty day moving average of $0.75 and a two-hundred day moving average of $2.10. The company has a market capitalization of $4.23 million, a PE ratio of -0.08 and a beta of 1.10. VolitionRX has a 12 month low of $0.30 and a 12 month high of $14.80.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. On average, equities analysts expect that VolitionRX will post -2.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VNRX has been the subject of several research analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark reissued a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.00.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.